F Formiga1, J Franch-Nadal, L Rodriguez, L Ávila, E Fuster. 1. Francesc Formiga, Geriatric Unit, Internal Medicine Department, Hospital Universitari de Bellvitge-IDIBELL, c/Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona (Spain), Tel.: + 34 932 607 699, Fax: +34 932 607 967, E-mail: fformiga@bellvitgehospital.cat.
Abstract
OBJECTIVES: The glycaemic goals for older patients with type 2 diabetes mellitus (DM) are recommended to avoid an HbA1c levels <7%. The purpose of this study was to analyse the glycaemic control and therapeutic management of older adults (≥65 years) with type 2 DM. DESIGN: Pooled analysis of patients enrolled in three Spanish cross-sectional epidemiological studies. SETTING: The study was conducted between 2009 and 2011 by primary care or specialist physicians. PARTICIPANTS: A total of 7,269 patients aged ≥65 years with type 2 DM. MEASUREMENTS: Sociodemographic, medical history, lifestyle habits, biochemical laboratory parameters, comorbidities, type 2 DM complications, and pharmacological treatment data collected from medical records. RESULTS: In total, data from 7,269 patients were analysed (mean age 73.4 years old; 48.4% male). A total of 10.9% of patients had HbA1c levels ≥8.5% and 43.2% <7%. The most common comorbidities were hypertension (82.0%) and dyslipidaemia (76.6%). The microvascular complications were mainly diabetic nephropathy (23.6%) and retinopathy (19.3%). Oral antidiabetic drugs (OADs) were taken by 70.5% of patients (sulphonylureas 65.3%), 4.1% were taking insulin alone and 25.4% took both insulin and an OAD. Half of the patients (51.0%) were taking a combination of OADs. CONCLUSION: In conclusion, more than half of older patients with type 2 DM had unsatisfactory management: approximately one in ten had inadequate glycaemic control (HbA1c ≥8.5%) despite hypoglycaemic drugs and four in ten were potentially overtreated (HbA1c <7%).
OBJECTIVES: The glycaemic goals for older patients with type 2 diabetes mellitus (DM) are recommended to avoid an HbA1c levels <7%. The purpose of this study was to analyse the glycaemic control and therapeutic management of older adults (≥65 years) with type 2 DM. DESIGN: Pooled analysis of patients enrolled in three Spanish cross-sectional epidemiological studies. SETTING: The study was conducted between 2009 and 2011 by primary care or specialist physicians. PARTICIPANTS: A total of 7,269 patients aged ≥65 years with type 2 DM. MEASUREMENTS: Sociodemographic, medical history, lifestyle habits, biochemical laboratory parameters, comorbidities, type 2 DM complications, and pharmacological treatment data collected from medical records. RESULTS: In total, data from 7,269 patients were analysed (mean age 73.4 years old; 48.4% male). A total of 10.9% of patients had HbA1c levels ≥8.5% and 43.2% <7%. The most common comorbidities were hypertension (82.0%) and dyslipidaemia (76.6%). The microvascular complications were mainly diabetic nephropathy (23.6%) and retinopathy (19.3%). Oral antidiabetic drugs (OADs) were taken by 70.5% of patients (sulphonylureas 65.3%), 4.1% were taking insulin alone and 25.4% took both insulin and an OAD. Half of the patients (51.0%) were taking a combination of OADs. CONCLUSION: In conclusion, more than half of older patients with type 2 DM had unsatisfactory management: approximately one in ten had inadequate glycaemic control (HbA1c ≥8.5%) despite hypoglycaemic drugs and four in ten were potentially overtreated (HbA1c <7%).
Authors: J Barrot-de la Puente; M Mata-Cases; J Franch-Nadal; X Mundet-Tudurí; A Casellas; J M Fernandez-Real; D Mauricio Journal: Int J Clin Pract Date: 2015-09-30 Impact factor: 2.503
Authors: Jonas Gordilho Souza; Daniel Apolinario; Regina Miksian Magaldi; Alexandre Leopold Busse; Flavia Campora; Wilson Jacob-Filho Journal: BMJ Open Date: 2014-02-12 Impact factor: 2.692
Authors: Medha N Munshi; Graydon S Meneilly; Leocadio Rodríguez-Mañas; Kelly L Close; Paul R Conlin; Tali Cukierman-Yaffe; Angus Forbes; Om P Ganda; C Ronald Kahn; Elbert Huang; Lori M Laffel; Christine G Lee; Sei Lee; David M Nathan; Naushira Pandya; Richard Pratley; Robert Gabbay; Alan J Sinclair Journal: Lancet Diabetes Endocrinol Date: 2020-10 Impact factor: 32.069
Authors: Peter Hanlon; Isabella Fauré; Neave Corcoran; Elaine Butterly; Jim Lewsey; David A McAllister; Frances S Mair Journal: BMJ Open Date: 2020-09-01 Impact factor: 2.692